MD126Y - Method for treating the nonspecific ulcerative colitis to persons of elderly age - Google Patents
Method for treating the nonspecific ulcerative colitis to persons of elderly age Download PDFInfo
- Publication number
- MD126Y MD126Y MDS20090149A MDS20090149A MD126Y MD 126 Y MD126 Y MD 126Y MD S20090149 A MDS20090149 A MD S20090149A MD S20090149 A MDS20090149 A MD S20090149A MD 126 Y MD126 Y MD 126Y
- Authority
- MD
- Moldova
- Prior art keywords
- ulcerative colitis
- ozone
- patients
- ozone concentration
- persons
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 12
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- 239000001301 oxygen Substances 0.000 claims abstract description 7
- 239000011780 sodium chloride Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 230000013872 defecation Effects 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002579 sigmoidoscopy Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- -1 sulfosalazine Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Inventia se refera la medicina, si anume la gastroenterologie si poate fi aplicata la tratarea colitei nespecifice ulceroase la persoanele de varsta inaintata. Metoda, conform inventiei, consta in aceea ca concomitent cu terapia de baza, zilnic, timp de 10 zile, se administreaza intramuscular 1 ml de solutie de BioR 0,5%, intravenos 250...300 ml de solutie de NaCl 0,9% ozonata cu concentratia ozonului de 3 mg/L, si rectal 100...500 cm3 de amestec de oxigen si ozon cu concentratia ozonului de 45 mg/L.The invention relates to medicine, namely gastroenterology, and may be applied to the treatment of nonspecific ulcerative colitis in the elderly. The method, according to the invention, consists in the fact that concomitant with the basic therapy, daily, for 10 days, 1 ml of 0.5% BioR solution is administered intramuscularly, intravenously 250 ... 300 ml of 0.9 NaCl solution % ozone with ozone concentration of 3 mg / L, and rectal 100 ... 500 cm3 of oxygen and ozone mixture with ozone concentration of 45 mg / L.
Description
Invenţia se referă la medicină, şi anume la gastroenterologie şi poate fi aplicată la tratarea colitei nespecifice ulceroase de formă uşoară, medie şi gravă la persoanele de vârstă înaintată. The invention relates to medicine, namely to gastroenterology and can be applied to the treatment of mild, moderate and severe nonspecific ulcerative colitis in elderly people.
Se cunoaşte metoda de tratament al colitei nespecifice ulceroase, care constă în aceea că pe lângă terapia de bază, care include derivaţi salazo ai sulfanilamidelor, se indică administrarea pe cale rectală a serului specific anti-HLA împotriva antigenilor de clasa 1, dizolvat cu albumină umană de la donatori, în doză de 100 ml, de trei ori, peste fiecare două zile [1]. The method of treatment of nonspecific ulcerative colitis is known, which consists in that in addition to the basic therapy, which includes salazo derivatives of sulfanilamides, the rectal administration of specific anti-HLA serum against class 1 antigens, dissolved with human albumin from donors, in a dose of 100 ml, three times, every two days is indicated [1].
Dezavantajul acestei invenţii este complexitatea aplicării ei, posibilitatea apariţiei reacţiilor adverse. Pe lângă aceasta, metoda dată nu ţine cont de particularităţile fiziologice ale persoanelor de vârstă înaintată. The disadvantage of this invention is the complexity of its application, the possibility of adverse reactions. In addition, this method does not take into account the physiological peculiarities of elderly people.
Problema pe care o rezolvă invenţia propusă este sporirea eficienţei tratamentului, micşorarea duratei lui, îmbunătăţirea restabilirii mucoasei intestinului gros. The problem solved by the proposed invention is increasing the efficiency of treatment, reducing its duration, and improving the restoration of the large intestine mucosa.
Problema se soluţionează prin aceea că concomitent cu terapia de bază, zilnic, timp de 10 zile, se administrează intramuscular 1 ml de soluţie de BioR 0,5%, intravenos 250...300 ml de soluţie de NaCl 0,9% ozonată cu concentraţia ozonului de 3 mg/L, şi rectal 100...500 cm3 de amestec de oxigen şi ozon cu concentraţia ozonului de 45 mg/L. The problem is solved by administering, simultaneously with the basic therapy, daily, for 10 days, 1 ml of 0.5% BioR solution intramuscularly, 250...300 ml of 0.9% ozonated NaCl solution intravenously with an ozone concentration of 3 mg/L, and 100...500 cm3 of a mixture of oxygen and ozone with an ozone concentration of 45 mg/L rectally.
Utilizarea în tratamentul complex a preparatului BioR, care manifestă, după observaţiile efectuate, în cazul tratării acestei patologii la persoanele de vârstă înaintată, acţiune antiinflamatoare asupra mucoasei intestinului gros, permite de a restabili o microfloră intestinală normală, care asigură o integritate fiziologică a multor sisteme din organism, ce ţin de formarea (maturarea) sistemului imunitar limforegulator general şi de imunitatea locală a mucoasei intestinale, de sistemul imunitar periferic şi de sistemul endocrin. Totodată, microflora intestinală realizează sinteza aminoacizilor, enzimelor şi a vitaminelor, participă la metabolismul general. De asemenea, posedând proprietăţi membranomodulatoare, preparatul BioR stimulează procesul de detoxicare, ce duce la normalizarea metabolismului ţesuturilor intestinului gros la nivel celular. Stimulând un segment al protecţiei umorale nespecifice, el micşorează inflamaţia ţesuturilor şi majorează imunitatea locală datorită sporirii activităţii fagocitare a leucocitelor. Administrarea pe cale rectală a amestecului de oxigen şi ozon în volum de 100...500 cm2 cu o concentraţie a ozonului de 45 mg/L asigură un efect hemostatic rapid. Administrarea intravenoasă a 250...300 mL de soluţie ozonată de NaCl 0,9%, cu concentraţia ozonului de 3 mg/L, contribuie la ameliorarea microcirculaţiei datorită normalizării propietăţilor reologice ale sângelui, precum şi datorită creşterii activităţii fibrinolitice, micşorării nivelului de fibrinogen şi agregării trombocitelor. Are loc normalizarea proceselor de oxidare peroxidă şi activarea sistemului antioxidant, totodată sporeşte esenţial oxigenarea ţesuturilor, are loc restabilirea diferitor procese metabolice. The use of the BioR preparation in complex treatment, which, according to the observations made, exhibits anti-inflammatory action on the mucosa of the large intestine in the case of treating this pathology in elderly people, allows to restore a normal intestinal microflora, which ensures the physiological integrity of many systems in the body, related to the formation (maturation) of the general lymphoregulatory immune system and local immunity of the intestinal mucosa, the peripheral immune system and the endocrine system. At the same time, the intestinal microflora synthesizes amino acids, enzymes and vitamins, participates in the general metabolism. Also, possessing membrane-modulating properties, the BioR preparation stimulates the detoxification process, which leads to the normalization of the metabolism of the tissues of the large intestine at the cellular level. Stimulating a segment of non-specific humoral protection, it reduces tissue inflammation and increases local immunity due to increased phagocytic activity of leukocytes. Rectal administration of a mixture of oxygen and ozone in a volume of 100...500 cm2 with an ozone concentration of 45 mg/L provides a rapid hemostatic effect. Intravenous administration of 250...300 mL of ozonated NaCl 0.9% solution with an ozone concentration of 3 mg/L contributes to the improvement of microcirculation due to the normalization of the rheological properties of the blood, as well as due to the increase in fibrinolytic activity, the decrease in the level of fibrinogen and platelet aggregation. The normalization of peroxide oxidation processes and the activation of the antioxidant system occur, at the same time, tissue oxygenation is significantly increased, and various metabolic processes are restored.
Astfel, aplicarea conform metodei a combinaţiei indicate a preparatelor medicamentoase permite de a obţine jugularea rapidă a procesului inflamator şi restabilirea mucoasei intestinului gros. Thus, the application of the indicated combination of medicinal preparations according to the method allows for rapid suppression of the inflammatory process and restoration of the large intestine mucosa.
Rezultatul invenţiei este vindecarea rapidă a pacienţilor şi restabilirea mucoasei intestinului gros. The result of the invention is the rapid healing of patients and the restoration of the large intestine mucosa.
Metoda revendicată a fost testată la un spital clinic al Ministerului Sănătăţii din Republica Moldova. The claimed method was tested at a clinical hospital of the Ministry of Health of the Republic of Moldova.
Sub observaţie s-au aflat 30 de persoane cu vârsta cuprinsă între 65 şi 74 de ani, care suferă de colită nespecifică ulceroasă. La toţi bolnavii în tabloul clinic s-au depistat hemoragii rectale, diaree, câte 12...15 acte de defecaţie în zi, sindrom dolor în regiunea iliacă stângă şi regiunea laterală stângă a abdomenului. Pacienţii, în funcţie de terapia efectuată, au fost divizaţi în două grupuri comparabile după toţi indicii. Primul grup experimental în număr de 15 pacienţi a fost tratat conform metodei propuse, iar grupul al doilea - de control, de asemenea, în număr de 15 pacienţi, a fost tratat conform metodei tradiţionale. 30 people aged 65 to 74 years, suffering from non-specific ulcerative colitis, were under observation. In all patients, the clinical picture revealed rectal bleeding, diarrhea, 12...15 acts of defecation per day, pain syndrome in the left iliac region and the left lateral region of the abdomen. Patients, depending on the therapy performed, were divided into two groups comparable in all indicators. The first experimental group, consisting of 15 patients, was treated according to the proposed method, and the second - control group, also consisting of 15 patients, was treated according to the traditional method.
Pe fondul terapiei efectuate la 10 pacienţi din primul grup, cuparea sindromului dolor a survenit în ziua a treia, iar la ceilalţi 5 pacienţi - în ziua a 10-a. În primele 3 zile la toţi pacienţii din primul grup s-a observat descreşterea numărului de acte de defecaţie până la 6...8 în zi. La a 10-a zi numărul de acte de defecaţie a ajuns la 1...2 în zi. La toţi pacienţii din primul grup la a 10-a zi lipseau acuzele, starea generală era bună. Against the background of the therapy carried out in 10 patients from the first group, the cessation of pain syndrome occurred on the third day, and in the other 5 patients - on the 10th day. In the first 3 days, all patients from the first group had a decrease in the number of defecations to 6...8 per day. On the 10th day, the number of defecations reached 1...2 per day. In all patients from the first group, on the 10th day, there were no complaints, the general condition was good.
Pe fondul terapiei efectuate la 4 pacienţi din grupul al doilea jugularea sindromului dolor a survenit în ziua a treia, iar la 9 pacienţi - în ziua a 10-a. În primele 3 zile la 5 pacienţi din grupul al doilea s-a observat descreşterea numărului de acte de defecaţie până la 6...8 în zi. Încă la 8 descreşterea numărului de acte de defecaţie până la 6...8 în zi a survenit în a 10-a zi. Numai la 5 pacienţi din grupul al doilea la a 10-a zi lipseau acuzele, starea generală era bună. Ceilalţi pacienţi prezentau diverse acuze. Against the background of the therapy carried out in 4 patients from the second group, the pain syndrome subsided on the third day, and in 9 patients - on the 10th day. In the first 3 days, in 5 patients from the second group, a decrease in the number of defecation acts to 6...8 per day was observed. In another 8, a decrease in the number of defecation acts to 6...8 per day occurred on the 10th day. Only in 5 patients from the second group on the 10th day were there no complaints, the general condition was good. The other patients had various complaints.
Metoda se realizează în modul următor. The method is carried out in the following way.
Pe fondul terapiei de bază, zilnic, timp de 10 zile, se administrează intramuscular 1 mL de soluţie de BioR 0,5%, intravenos 250...300 mL de soluţie ozonată de NaCl 0,9%, cu concentraţia ozonului de 3 mg/L, şi rectal 100...500 cm2 de un amestec din oxigen şi ozon cu concentraţia ozonului de 45 mg/L. Against the background of basic therapy, daily, for 10 days, 1 mL of 0.5% BioR solution is administered intramuscularly, 250...300 mL of 0.9% ozonated NaCl solution intravenously, with an ozone concentration of 3 mg/L, and 100...500 cm2 of a mixture of oxygen and ozone with an ozone concentration of 45 mg/L is administered rectally.
Exemplu Example
Bolnavul A., 68 ani, s-a adresat acuzând scaune frecvente cu conţinut lichid cu sânge, slăbiciune generală pronunţată, dureri spastice în abdomen, frisoane, inapetenţă. A fost efectuată investigaţia clinică şi paraclinică, în baza căreia s-a stabilit diagnosticul clinic: colită nespecifică ulceroasă cronică, formă gravă, în fază de acutizare. La rectoromanoscopie: mucoasă edemată, eroziuni, hemoragii de contact. Patient A., 68 years old, complained of frequent stools with liquid content and blood, pronounced general weakness, spastic pain in the abdomen, chills, loss of appetite. Clinical and laboratory investigations were performed, based on which the clinical diagnosis was established: chronic nonspecific ulcerative colitis, severe form, in the acute phase. On sigmoidoscopy: edematous mucosa, erosions, contact hemorrhages.
A fost efectuată terapia de bază incluzând: un regim mecanic de cruţare, terapia cu infuzii, vitamine, antibiotice, preparate sedative, antidiareice, sulfosalazin, hormoni corticosteroizi. Din prima zi de tratament pe fondul terapiei de bază, zilnic i s-a administrat intramuscular 1 mL de soluţie de BioR 0,5%, intravenos 250 mL de soluţie ozonată de NaCl 0,9% cu concentraţia ozonului de 3 mg/L, şi rectal 300 cm2 de un amestec din oxigen şi ozon cu concentraţia ozonului de 45 mg/L. După administrarea a treia a amestecului de oxigen şi ozon s-a obţinut un efect clinic stabil: s-a micşorat frecvenţa actelor de defecaţie, au dispărut acuzele prezentate. Peste o săptămână de la începutul tratamentului a fost efectuată o rectoromanoscopie repetată: a dispărut edemul mucoasei, au încetat hemoragiile de contact, mucoasa este lucioasă, sunt vizibile unele eroziuni. Termenul de remisie 10 luni. Basic therapy was performed including: a mechanical sparing regimen, infusion therapy, vitamins, antibiotics, sedatives, antidiarrheals, sulfosalazine, corticosteroid hormones. From the first day of treatment on the background of basic therapy, daily 1 mL of BioR 0.5% solution was administered intramuscularly, 250 mL of ozonated NaCl 0.9% solution with an ozone concentration of 3 mg/L was administered intravenously, and 300 cm2 of a mixture of oxygen and ozone with an ozone concentration of 45 mg/L was administered rectally. After the third administration of the mixture of oxygen and ozone, a stable clinical effect was obtained: the frequency of defecation decreased, the complaints disappeared. A week after the start of treatment, a repeated sigmoidoscopy was performed: the mucosal edema disappeared, contact hemorrhages stopped, the mucosa is shiny, some erosions are visible. The remission period was 10 months.
1. RU 2089218 C1 1997.09.10 1. RU 2089218 C1 1997.09.10
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20090149A MD126Z (en) | 2009-07-31 | 2009-07-31 | Method for treating the nonspecific ulcerative colitis to persons of elderly age |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20090149A MD126Z (en) | 2009-07-31 | 2009-07-31 | Method for treating the nonspecific ulcerative colitis to persons of elderly age |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD126Y true MD126Y (en) | 2010-01-29 |
| MD126Z MD126Z (en) | 2010-08-31 |
Family
ID=43568888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20090149A MD126Z (en) | 2009-07-31 | 2009-07-31 | Method for treating the nonspecific ulcerative colitis to persons of elderly age |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD126Z (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2089218C1 (en) * | 1994-02-22 | 1997-09-10 | Татьяна Александровна Суслова | Method of treatment of nonspecific ulcer colitis |
| RU2089211C1 (en) * | 1995-07-05 | 1997-09-10 | Московская медицинская академия им.И.М.Сеченова | Agent for chronic prostatitis treatment |
-
2009
- 2009-07-31 MD MDS20090149A patent/MD126Z/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD126Z (en) | 2010-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5731325A (en) | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents | |
| RU2707089C2 (en) | Combined composition | |
| JP2001064192A (en) | Migration inhibitor for langerhans cell and antigen presentation inhibitor | |
| JP3721196B2 (en) | Use of magnesium-based products for the treatment or prevention of neoplastic and autoimmune diseases | |
| US20130123319A1 (en) | Medthod of Treating a systemic inflammatory disorder and damaged internal tissues | |
| US6558656B2 (en) | Oral and topical compositions and methods related thereto in the treatment of acne | |
| US6720011B1 (en) | Injectable composition for cancer treatment | |
| Pătraşcu et al. | Ulcerated necrobiosis lipoidica to a teenager with diabetes mellitus and obesity | |
| Meaume et al. | Efficacy and safety of ornithine alpha-ketoglutarate in heel pressure ulcers in elderly patients: results of a randomized controlled trial | |
| RU2086242C1 (en) | Method of nonbearing pregnancy treatment | |
| MD126Y (en) | Method for treating the nonspecific ulcerative colitis to persons of elderly age | |
| RU2487737C1 (en) | Method of treating gastric or duodenal ulcer | |
| ALTSHULER et al. | Clinical use of amino acids for the maintenance of nitrogen equilibrium | |
| RU2132685C1 (en) | Method for treating benign hyperplasia of prostate | |
| RU2359664C1 (en) | Pharmaceutical injection composition on basis of tilorone for treatment of purulent-destructive processes with signs of immune insufficiency | |
| US6270756B1 (en) | Weight loss induced by alpha interferon and gamma interferon | |
| RU2099061C1 (en) | Method for treating the cases of neurodermite | |
| Suzman | The clinical application of corticotropin and cortisone therapy: a report of 247 cases | |
| RU2121841C1 (en) | Method of treatment of patients with trophic ulcers | |
| RU2231359C1 (en) | Method for treatment of skin angiitis ulcerous forms | |
| TW201420130A (en) | Liquid agent containing dissolved carbon dioxide and administrating method thereof | |
| RU2386412C1 (en) | Method of psoriasis treatment | |
| RU2357747C1 (en) | Method of psoriatic disease treatment | |
| RU2018320C1 (en) | Method for treatment of juvenile rheumatic arthritis | |
| RU2195928C2 (en) | Method for antibioticotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |